Over the last few years the use of gliptins in South Asians and Indians has increased dramatically. This has been mirrored with evidence of the decreasing benefits of sulfonylureas. Sulfonylureas used to and still is a drug that is very commonly used. The fear that use of sulfonylureas results in an increase in the death or failure of beta cells has led many clinicians to use the medication with caution.
Gliptins initially made their appearance in 2006. This group of medication are DPP-4 inhibitors. The group of enzymes were discovered as far back as 1967 but it took close to 40 years to be able to utilise them for our benefit. The method of action is to increase incretins. This increase in the levels of incretins results in decrease in the amount of glucagon released. Glucagon is a hormone that increases the levels of glucose. Gliptins actions do not stop there but they also increase the amount of insulin being released, slow the transit of food in the gastrointestinal tract and lower the levels of glucose in the body. The medication though needs to be used with caution in patients with deranged liver function tests and also with any history of pancreatic disease.

